Support for amiloride as a spironolactone alternative in resistant hypertension
The diuretic amiloride may be a suitable treatment alternative to spironolactone for patients with resistant hypertension, suggests a study published in JAMA.
Childhood cancer survivors might benefit from cochlear implants
Childhood cancer survivors with severe to profound sensorineural hearing loss following chemotherapy or radiotherapy may be candidates for cochlear implants, US researchers believe.
Agnostic dMMR tumour PD-1 inhibitor approach may avoid resection
Patients with deficient mismatch repair (dMMR) cancers may not require surgery after 6 months of neoadjuvant treatment with the PD-1 inhibitor dostarlimab, suggests research published in The New England Journal of Medicine.
Lorundrostat shows promise for uncontrolled, treatment-resistant hypertension
Lorundrostat, a selective aldosterone synthase inhibitor, shows blood pressure -lowering potential in people with uncontrolled and treatment-resistant hypertension, according to the Advance-HTN trial.
Polygenic risk score may improve prostate cancer screening
A polygenic risk score could help direct prostate cancer screening towards those at highest risk for the disease, the BARCODE1 investigators report.
CSF tau may flag hippocampal atrophy in new-onset refractory status epilepticus
Elevated total tau in cerebral spinal fluid may indicate initial brain injury in patients with cryptogenic new-onset refractory status epilepticus and predict subsequent hippocampal atrophy, suggest study findings.
Intensive systolic blood pressure control reduces CVD mortality risk in the over 80s
Antihypertensive treatment of patients over the age of 80 years to a target systolic blood pressure below 130 mmHg could significantly reduce their risk of death from cardiovascular disease by 26%, suggests an analysis of NHANES data.
Half-dose apixaban noninferior for preventing recurrent VTE in cancer patients
For patients with active cancer and venous thromboembolism, a reduced dose of apixaban is noninferior to the standard dose for preventing recurrent thromboembolic episodes and significantly reduces the risk of clinically relevant bleeding, report the API-CAT investigators.
‘Accelerated’ onset of aging-related disease highlighted for childhood cancer survivors
Children who survive for at least 5 years after treatment for cancer are 2.7 times more likely to develop one of eight aging-related chronic health conditions before the age of 65 years than members of the general population, US researchers suggest.
Chemoprevention use after TNBC ‘may be reasonable’
Research indicates that women with triple-negative breast cancer might benefit from low-dose tamoxifen to reduce the risk of recurrent or new primary disease.
